| dc.identifier.citation | [1] Creager MA, and Lüscher TF.2003. Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I. Circulation. 2003; 108:1527-1532. [2] McGuire KD. 2012. Diabetes and The Cardiovasculer System. Braunwald’s Hearth Disease. 9th ed. Elsevier. Philadelphia. 2012: 1392-1409. [3] American Diabetes Association. 2007. Diagnosis and classification of diabetes mellitus. Diabetes Care. [4] Clayton, W. Jr. 2009. A Review of The Pathophysiology, Classification, and Treatment of Foot Ulcers in Diabetic Patients. January, 27 2010 through ProQuest Health and Medical Complete Bernard, 2007 [5] Jones R. 2007. Exploring The Complex Care of The Diabetic Foot Ulcer. JAAPA. [6] Bernard, L. (Chairman Working Group). 2007. Clinical practice guidelines: Management of diabetic foot infections. Medicine et maladies infectieuses, 37:14-25. [7] Frykberg, R.G., Armstrong,. D.G., Giurini, J., Edwards, A., Kravette, M., Kravitz, S., Ross, C., Stavosky, J., Stuck, R., and Vanore, J. 2000. Diabetic Foot Disorders : A Clinical Practice Guideline. Journal of Foot & Ankle Surgery, 39:S1-S60. [8] Van Baal, J.G. 2004. Surgical treatment of the Infected Diabetic Foot. Clinical Infectious Diseases, 39: S 123-8. [9] Widatalla, A.H., Mahadi, S., Shawer, M.A., Elsayem, H.A., and Ahmed, M.E. 2009. Implementation of diabetic foot ulcer classification system for research purposes to predict lower extremity amputation. Int J Diabetes Dev Ctries, 29:1–5. [10] Lobmann, R., Schultz, G., and Lehnert, H. 2005. Proteases and Diabetic Foot Syndrome: Mechanisms and Therapeutic Implications. Diabetes care, 28(2):462-71. [11] Goldberg, M.T., Han, Y-P., Yan, C., Shaw, M.C., and Garner, M.L. 2007. TNF-α Suppresses α-Smooth Muscle Actin Expression in Human Dermal Fibroblasts: An Implication for Abnormal Wound Healing. J Invest Dermatol, 127(11): 2645–55. [12] Leung, P.C., Wong M.W.N., and Wong, W.C. 2008. Limb salvage in extensive diabetic foot ulceration: an extended study using a herbal supplement. Hong Kong Med J, 14:29-33. [13] Siqueira, M. F., Li, J., Chehab, L., Desta, T., Chino, T., Krothpali, N., Behl, Y., Alikhani, M., Yang, J., Braasch, C., and Graves, DT., 2010. Impaired wound healing in mouse models of diabetes is mediated by TNF-α dysregulation and associated with enhanced activation of forkhead box O1 (FOXO1). Diabetologia, 53(2): 378–88. [14] Maltezoz, E., Papazoglou, D., Exiara, T., Papazoglou, L., Karathanasis, E., Christakidis, D., and Ktenidou-Kartali, S. 2002. Tumour Necrosis Factor-α Levels in Non-diabetic Offspring of Patients with Type 2 Diabetes Mellitus. The Journal of International Medical Research, 30 : 576-83. [15] Frank, S., Hubner, G., Breier, G., Longaker, M.T., Greenhalgh, D.G., and Werner, S. 1995. Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes: Implication for Normal and Impaired Wound Healing, The Journal of Biological Chemistry, 270:12607-13 [16] Brem, H., and Tomic-Canic, M. 2007. Cellular and molecular basis of wound healing in diabetes. J. Clin. Invest. 117:1219–22. [17] Quattrini, C., Jeziorska, M., Boulton, A.J.M., and Malik, R.A. 2008. Reduced Vascular Endothelial Growth Factor Expression and Intra-Epidermal Nerve Fiber Loss in Human Diabetic Neuropathy. Diabetes Care, 31 :140-5. [18] Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002;27:19-26. [19] Ware CF., 2008. TNF-related cytokines in immunity. In: Paul WE, editor. Fundamental immunology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:776-803. [20] Bertazza L., and Mocellin S., 2008. Tumor necrosis factor (TNF) biology and cell death. Front Biosci 2008;13:2736-43. [21] Black RA, at al., 1997. "A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells". Nature 385 (6618): 729–33. [22] Oppenheim JJ., and Ruscetti FW. 2001. Cytokines in Medical Immunology, tenth edition by Parslow GT; Stites PD, Terr IA, Imboden BJ, Lange Medical Book/Mc Graw-Hill, Medical Publishing Division, p.148-164. [23] Ware CF., 2008. TNF-related cytokines in immunity. In: Paul WE, editor. Fundamental immunology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:776-803. [24] Roitt I, Brostoff J, Male D., 2001. Cytokines and cytokines receptors in Immunology sixth edition Billiere Tindall, Churchill. Livingstone. Mosby WB Saunders, p.119-129 [25] Abbas AK., Lichtman AH., Pober JS., (2000), Cytokines in Celluler and Molecular Immunology, International edition, WB Sounders Co, Philadelphia, London, Toronto, Monreal, Sydney, Tokyo, p.240-260. [26] Dong Y., He L., and Chen F., 2005. Enhancement of wound healing by taspine and its effect on fibroblast. Zhang Yao Cai 28 (7) : 579-582 (Abstract) [27] Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-a suppresses adipocye-specific genes and activates expression of preadipocyte genes in 3T3-L1adipocytes: nuclear factor-kB activation is obligatory. Diabetes 2002; 51:1319–36. [28] Bruunsgaard H, Pedersen M, Pedersen BK., 2001. Aging and proinflammatory cytokines. Curr Opin Hematol 2001; 8:131–6. [29] Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response pf patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001; 65:510–16. [30] Straczkowski M, Kowalska I, Stepien A, Dzienis-Straczowska S, Szelachowska M, Kinalska I. Increased plasma-soluble tumor necrosis factor-alpha receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes Care 2002; 25:1824–8. [31] H. Knobler and A. Schattner., 2005. TNF-a, chronic hepatitis C and diabetes: a novel triad. Q J Med 2005; 98:1–6 [32] Wallace, H.,J., and Stacey, M.,C. 1998. Level of tumour Necrosis Factor-α (TNF-α) and Soluble TNF Receptors in Chronic Venous Leg Ulcer – Correlations to Healing Status. J Invest Dermatol ; 110 (3) : 292-6. | in_ID |
